Table 1.
Compound-dependent parameters of eight tyrosine kinase inhibitors with testosterone as internal standard (IS) in UHPLC–MS/MS analysis.
| Analyte | Precursor ion (m/z) | Product ion (m/z) | Dwell time (ms) | DP (V) | CE (V) | CXP (V) |
|---|---|---|---|---|---|---|
|
| ||||||
| Erlotinib | 394.3 | 278.3 | 100 | 60 | 40 | 3.6 |
| Sorafenib | 465.1 | 270.2 | 100 | 55 | 30 | 4.0 |
| Sunitinib | 399.4 | 283.1 | 100 | 50 | 38 | 3.5 |
| Dasatinib | 488.3 | 401.2 | 100 | 67 | 40 | 5.0 |
| Lapatinib | 581.2 | 365.2 | 100 | 87 | 48 | 5.0 |
| Nilotinib | 530.3 | 289.2 | 100 | 84 | 39 | 3.0 |
| Pazopanib | 438.3 | 357.3 | 100 | 88 | 38 | 4.0 |
| Axitinib | 387.0 | 356.2 | 100 | 57 | 26 | 5.0 |
| Testosterone (IS) | 288.9 | 97.0 | 100 | 57 | 39 | 4.0 |
DP: declustering potential; CE: collision energy; CXP: collision cell exit potential.